{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:14:04Z","timestamp":1781478844197,"version":"3.54.1"},"reference-count":48,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Reactivation of hepatitis B is characterized by a sudden increase in hepatitis B virus (HBV) replication in a patient with prior evidence of resolved or inactive HBV infection. Although HBV reactivation can occur spontaneously, it usually occurs after chemotherapy, immunosuppression (organ transplantation) or an alteration in immune function (therapy for autoimmune disease, human immunodeficiency virus infection). The clinical presentation cases can vary, ranging from a subclinical, asymptomatic course to severe acute hepatitis and even death. Although reactivation of HBV is mainly found in HBsAg\u2010positive patients, it can be observed in serologically recovered anti\u2010hepatitis B core antibody (HBc)\u2010positive, HBsAg\u2010negative patients. Serum HBV DNA typically increases during immune suppression, followed by a disease flare and HBV DNA clearance following immune restoration after immune suppression is stopped. In organ transplant recipients, without immune reconstitution, high HBV DNA levels can lead to fibrosing cholestatic hepatitis related to the direct cytopathic effect of HBV. Several randomized, controlled trials and meta\u2010analyses have shown that reactivation can be prevented by lamivudine prophylaxis. Screening for HBsAg and anti\u2010HBc should be performed before beginning immunosuppressive treatment and routine prophylaxis is recommended in HBsAg\u2010positive patients. The optimal duration of prophylaxis remains to be determined. In anti\u2010HBc\u2010positive patients with or without anti\u2010hepatitis B surface antigen, alanine transaminase and HBV DNA levels should be closely monitored and antiviral therapy should be started when HBV reactivation is confirmed. The use of new more potent nucleos(t)ides analogues with lower resistance rates would seem to be logical; however, experience with these drugs in the prophylaxis and treatment of severe HBV reactivation is limited.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2010.02396.x","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T15:16:48Z","timestamp":1294154208000},"page":"104-110","source":"Crossref","is-referenced-by-count":55,"title":["The difficulties of managing severe hepatitis B virus reactivation"],"prefix":"10.1111","volume":"31","author":[{"given":"Bruno","family":"Roche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"661","article-title":"Chronic hepatitis B","volume":"50","author":"Lok AS","year":"2009","journal-title":"update 2009"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0182"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.05.014"},{"key":"e_1_2_7_5_2","first-page":"1363","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients","volume":"53","author":"Esteve M","year":"2004","journal-title":"need for primary prophylaxis"},{"key":"e_1_2_7_6_2","first-page":"983","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases","volume":"65","author":"Calabrese LH","year":"2006","journal-title":"assessment and preventive strategies"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11913-1"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.004"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90623-3"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22945"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90599-G"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.026"},{"key":"e_1_2_7_13_2","first-page":"844","article-title":"A revisit of prophylactic lamivudine for chemotherapy\u2010associated hepatitis B reactivation in non\u2010Hodgkin's lymphoma","volume":"47","author":"Hsu C","year":"2008","journal-title":"a randomized trial"},{"key":"e_1_2_7_14_2","first-page":"519","article-title":"Systematic review","volume":"148","author":"Loomba R","year":"2008","journal-title":"the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy"},{"key":"e_1_2_7_15_2","first-page":"89","article-title":"Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients","volume":"15","author":"Katz LH","year":"2008","journal-title":"systematic review and meta-analysis"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.195834"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(88)90127-4"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.322"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(96)82604-7"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21051"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(75)80054-0"},{"key":"e_1_2_7_22_2","first-page":"299","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"62","author":"Yeo W","year":"2000","journal-title":"a prospective study of 626 patients with identification of risk factors"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2324"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601699"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070763"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50220"},{"key":"e_1_2_7_27_2","first-page":"553","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy","volume":"70","author":"Yeo W","year":"2003","journal-title":"a prospective study"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199004000-00011"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703614"},{"key":"e_1_2_7_30_2","first-page":"14","article-title":"Adoptive transfer of immunity to HBV in liver transplant patients","volume":"13","author":"Shouval D.","year":"2007","journal-title":"a step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon?"},{"key":"e_1_2_7_31_2","first-page":"20","article-title":"Review article","volume":"31","author":"Shale MJ","year":"2010","journal-title":"chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.10.006"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318068d1dd"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80017-2"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1990.tb00449.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20939"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008206519571"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03239.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200501203520324"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21486"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35352"},{"key":"e_1_2_7_42_2","first-page":"349","article-title":"Adefovir dipivoxil for wait\u2010listed and post\u2010liver transplantation patients with lamivudine\u2010resistant hepatitis B","volume":"13","author":"Schiff E","year":"2007","journal-title":"final long-term results"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.11.007"},{"key":"e_1_2_7_44_2","first-page":"227","article-title":"EASL Clinical Practice Guidelines","volume":"50","author":"European Association For The Study Of The Liver.","year":"2009","journal-title":"management of chronic hepatitis B"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23346"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hep.2010.06.043"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00385.x"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00419-1"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06465.x"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02396.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2010.02396.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T07:55:10Z","timestamp":1694591710000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2010.02396.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":48,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1478-3231.2010.02396.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02396.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}